1. A Practical Strategy for Exploring the Pharmacological Mechanism of Luteolin Against COVID-19/Asthma Comorbidity: Findings of System Pharmacology and Bioinformatics Analysis
- Author
-
Yi-Zi Xie, Chen-Wen Peng, Zu-Qing Su, Hui-Ting Huang, Xiao-Hong Liu, Shao-Feng Zhan, and Xiu-Fang Huang
- Subjects
Vascular Endothelial Growth Factor A ,bioinformatics analysis ,Immunology ,Anti-Inflammatory Agents ,Serum Albumin, Human ,Comorbidity ,Antiviral Agents ,Antioxidants ,Drug Discovery ,Immunology and Allergy ,Humans ,Immunologic Factors ,Protein Interaction Maps ,luteolin ,Original Research ,Interleukin-6 ,SARS-CoV-2 ,Tumor Necrosis Factor-alpha ,COVID-19 ,Computational Biology ,system pharmacology ,RC581-607 ,asthma ,Molecular Docking Simulation ,Immunologic diseases. Allergy ,Tumor Suppressor Protein p53 ,Proto-Oncogene Proteins c-akt ,Signal Transduction - Abstract
Asthma patients may increase their susceptibility to SARS-CoV-2 infection and the poor prognosis of coronavirus disease 2019 (COVID-19). However, anti-COVID-19/asthma comorbidity approaches are restricted on condition. Existing evidence indicates that luteolin has antiviral, anti-inflammatory, and immune regulation capabilities. We aimed to evaluate the possibility of luteolin evolving into an ideal drug and explore the underlying molecular mechanisms of luteolin against COVID-19/asthma comorbidity. We used system pharmacology and bioinformatics analysis to assess the physicochemical properties and biological activities of luteolin and further analyze the binding activities, targets, biological functions, and mechanisms of luteolin against COVID-19/asthma comorbidity. We found that luteolin may exert ideal physicochemical properties and bioactivity, and molecular docking analysis confirmed that luteolin performed effective binding activities in COVID-19/asthma comorbidity. Furthermore, a protein–protein interaction network of 538 common targets between drug and disease was constructed and 264 hub targets were obtained. Then, the top 6 hub targets of luteolin against COVID-19/asthma comorbidity were identified, namely, TP53, AKT1, ALB, IL-6, TNF, and VEGFA. Furthermore, the enrichment analysis suggested that luteolin may exert effects on virus defense, regulation of inflammation, cell growth and cell replication, and immune responses, reducing oxidative stress and regulating blood circulation through the Toll-like receptor; MAPK, TNF, AGE/RAGE, EGFR, ErbB, HIF-1, and PI3K–AKT signaling pathways; PD-L1 expression; and PD-1 checkpoint pathway in cancer. The possible “dangerous liaison” between COVID-19 and asthma is still a potential threat to world health. This research is the first to explore whether luteolin could evolve into a drug candidate for COVID-19/asthma comorbidity. This study indicated that luteolin with superior drug likeness and bioactivity has great potential to be used for treating COVID-19/asthma comorbidity, but the predicted results still need to be rigorously verified by experiments.
- Published
- 2022